Metabolomic Profiling of Brain Protective Effect of Edaravone on Cerebral Ischemia-Reperfusion Injury in Mice

Hui-fen Ma†, Fan Zheng†, Lin-jie Su, Da-wei Zhang, Yi-ning Liu, Fang Li, Yuan-yuan Zhang, Shuai-shuai Gong* and Jun-ping Kou*

State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Pharmacology of Chinese Materia Medica, School of Traditional Pharmacy, China Pharmaceutical University, Nanjing, China

Edaravone (EDA) injection has been extensively applied in clinics for treating stroke. Nevertheless, the metabolite signatures and underlying mechanisms associated with EDA remain unclear, which deserve further elucidation for improving the accurate usage of EDA. Ischemia stroke was simulated by intraluminal occlusion of the right middle cerebral artery for 1 h, followed by reperfusion for 24 h in mice. Brain infarct size, neurological deficits, and lactate dehydrogenase (LDH) levels were improved by EDA. Significantly differential metabolites were screened with untargeted metabolomics by cross-comparisons with pre- and posttreatment of EDA under cerebral ischemia/reperfusion (I/R) injury. The possibly involved pathways, such as valine, leucine, and isoleucine biosynthesis, and phenylalanine, taurine, and hypotaurine metabolisms, were enriched with differential metabolites and relevant regulatory enzymes, respectively. The network of differential metabolites was constructed for the integral exhibition of metabolic characteristics. Targeted analysis of taurine, an important metabolic marker, was performed for further validation. The level of taurine decreased in the MCAO/R group and increased in the EDA group. The inhibition of EDA on cerebral endothelial cell apoptosis was confirmed by TdT-mediated dUTP nick-end labeling (TUNEL) stain. Cysteine sulfinic acid decarboxylase (CSAD), the rate-limiting enzyme of taurine generation, significantly increased along with inhibiting endothelial cell apoptosis after treatment of EDA. Thus, CSAD, as the possible new therapeutic target of EDA, was selected and validated by Western blot and immunofluorescence. Together, this study provided the metabolite signatures and identified CSAD as an unrecognized therapeutic intervention for EDA in the treatment of ischemic stroke via inhibiting brain endothelial cell apoptosis.

Keywords: metabolomic, edaravone, ischemia stroke, taurine, endothelial cells

Abbreviations: CSAD, cysteine sulfinic acid decarboxylase; EDA, edaravone; LDH, lactate dehydrogenase; MCAO/R, middle cerebral artery occlusion/reperfusion; TUNEL, TdT-mediated dUTP nick-end labeling; H&E, hematoxylin and eosin; EC, endothelial cell; I/R, ischemia/reperfusion.
INTRODUCTION

Stroke, one of the neurovascular diseases, is the leading cause of disability and death globally, resulting from an increasing burden of vascular risk factors. Ischemic stroke is the most common type, accounting for 70% of all strokes (Benjamin et al., 2019; Montaner et al., 2020). Although the precise mechanism underlying ischemic injury has not been fully elucidated, vascular pathology has been reported the most common cause. As part of the vascular pathologies, endothelial cell (EC) death could affect the surrounding cellular environment, which made it a potential target mechanism for the treatment and prevention of stroke, and ECs line the entire microvasculature and are also important for maintaining normal brain function. Therefore, it is necessary to choose the appropriate drugs for ischemic stroke.

Edaravone injection (EDA), as a commonly neurovascular protective agent, has been widely used in patients with acute ischemic stroke owing to its scavenging effect on oxygen-free radical and neurovascular protective effects (Kikuchi et al., 2013). It has been proven that EDA attenuates the Ca$^{2+}$-induced swelling of mitochondria and inhibits neuron apoptosis by decreasing the expression of Fas-associated death domain protein, death-associated protein, and caspase-8 immunoreactivity in the middle cerebral artery occlusion (MCAO) model (Zhang et al., 2005). EDA could suppress the response to endoplasmic reticulum stress and subsequent apoptotic signaling in hypoxic/ischemic injury and exhibit neuroprotective effects via its antioxidant actions, such as suppression of lipid peroxidation and oxidant-induced DNA damage (Amemiya et al., 2005; Yung et al., 2007). In addition, EDA also could inhibit vascular endothelial growth factor (VEGF) expression, aquaporin-4 expression, nuclear factor-xB (NF-xB), inducible nitric oxide synthase (iNOS), cytokines, cyclooxygenase-2, reactive oxygen species (ROS) generation, and ROS-induced inflammatory reactions in stroke mice and patients (Kikuchi et al., 2013). However, few of the literature comprehensively elucidate activity characteristics of EDA; thus, further studies are still needed.

Metabolites are small molecules (typically <1.5 kDa), including lipids, amino acids, carbohydrates, and nucleotides, that could reflect the downstream function of the gene, protein expression, and environmental changes, such as drug intake; as a result, metabolome could provide information about related mechanisms (Shah et al., 2012). What is more, disease-specific metabolites can be biomarkers for the diagnosis of diseases and provide reference for the precise use of drugs in the clinic. The functional characteristics of Huang-Lian-Jie-Du decoction and gross saponins of Tribulus terrestris fruit were elucidated for ischemic stroke with metabolomics (Fu et al., 2019; Wang et al., 2019). By contrast, the value of metabolites of EDA for stroke has not been systematically studied. Therefore, the metabolomics was selected to investigate the potential mechanism of EDA.

Herein, we intended to discover the therapeutic mechanism of EDA for stroke as comprehensively as possible according to the metabolite variation characteristics. In this study, untargeted metabolic profiling was applied to examine the serum and urine metabolic signature of EDA for improving stroke. The metabolic network was constructed with differential metabolites. Finally, we performed targeted metabolic profiling and verified the potential therapeutic targets.

MATERIALS AND METHODS

Chemicals and Reagents

The standard compounds of taurine and caffeic acid were obtained from Shanghai Yuanye Bio-technology Co., Ltd. (Shanghai, China). Deionized water used in the experiment was supplied by a Milli-Q Academic ultrapure water system (Milford, Millipore, United States). Acetonitrile and methanol were obtained from Merck (Chromatographic, Germany); formic acid was obtained from Tedia (Chromatographic, United States). Edaravone injection was obtained from China National Medicines Guorui pharmaceutical Co., Ltd. (Anhui, China; lot number: 2005018). The lactate dehydrogenase (LDH) assay kit was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China), and cysteine sulfonic acid decarboxylase (CSAD) was obtained from Abcam (Cambridge, England).

Animals and Middle Cerebral Artery Occlusion/Reperfusion (MCAO/R) Model

Adult male specific-pathogen-free (SPF) C57BL/6J mice weighing 18–22 g were obtained from the Experimental Animal Research Centre of Yangzhou University (Yangzhou, China; certificate no SCXK 2017–0007). All experimental protocols were performed according to the National Institutes of Health (NIH) guidelines and the research was approved by the Institutional Animal Care and Use Committee of the Animal Ethics Committee of the School of Chinese Materia Medica, China Pharmaceutical University. All mice were housed with a 12:12 h light–dark cycle at 23 ± 1°C. Prior to experiments, mice were split randomly into three groups: sham, MCAO/R, and MCAO/R + EDA. Stroke was induced by the MCAO/R model in mice as reported previously (Cao et al., 2016). In addition, the right middle cerebral artery was occluded with a blunt-tip 6-0 nylon monofilament for 1 h. Then the animals were reperfused by the careful withdrawal of the filament. Sham-operated control mice underwent the same surgical procedures except for the occlusion by nylon monofilament. EDA was administrated intraperitoneally to mice with 3 mg/kg (refer to the clinical dose) after 1 h of ischemia, the remaining model mice were given an equal volume of normal saline. Neurological function was evaluated at 24 h after reperfusion. Neurological deficit was graded on a score of 0–4 as previously reported (Cao et al., 2016) with slight modifications, as follows: 0, no observable deficit; 1, forelimb flexion and preference to walk in one direction; 2, unable to walk straight or to turn in both directions, circling to the affected side when held by the tail on the bench; 3, circling on the spot and walking circling; and 4, no spontaneous locomotor activity or barrel rolling, upon stimulation circling.
Hematoxylin and Eosin (H&E) Staining
H&E staining was used for histomorphological analysis. In short, brain slices were put into hematoxylin and eosin solution, dehydrated in gradient ethanol solution again, treated with dimethylbenzene, and covered with coverslips. The pathological images were scanned with a digital pathological section scanner (Hamamatsu, Japan) and analyzed with NDPView2 software.

Transmission Electron Microscopy
After I/R, mice were euthanized and perfused by normal saline. Then, the whole brains were taken out, frozen at −20°C followed by cutting into 1 mm thick slices rapidly. These brain slices were incubated in 1% TTC for 10 min at 37°C. The infarcted areas were analyzed with ImageJ software (NIH, Bethesda, MD).

Untargeted Metabolomics Analysis
Sample Pretreatment
Serum and urine of mice were collected after 24 h reperfusion. After standing for about 60 min, the blood was centrifuged with 3,500 r/min for 10 min at 15°C. The obtained serum samples were sub-packed and stored at −80°C until the analysis. Urine samples were collected at 4°C and kept at −80°C until the analysis. 200 μl of serum and urine were used for untargeted metabolomics analysis and 600 μl of methanol was added into samples for precipitating protein. Samples were subsequently centrifuged (13,000 rpm, 15 min) at 4°C followed by swirling 60 s. The supernatant was transferred to a tube and dried under a gentle stream of nitrogen at room temperature. Then, the residue was dissolved with 200 μl methanol and centrifuged (13,000 rpm, 15 min) at 4°C for further analysis.

HPLC-Q-TOF/MS Analysis
The detection of metabolites in urine and serum samples was performed on an Agilent Technologies 6540 Accurate-Mass Q-TOF LC/MS (United States) with electrospray ionization (ESI) source and the data were collected by a mass hunter workstation. The eluant A and B were deionized water (0.1% formic acid) and acetonitrile (0.1% formic acid), respectively. Serum analyses were achieved on a SyngentTM Fusion-RP C18 column (50 × 2 mm i.d., 2.5 μm) with a gradient elution program: 0–5 min, 5–5% B; 5–10 min, 5–30% B; 10–15 min, 30–60% B; 15–20 min, 60–70% B; 20–22 min, 70–80% B; 22–25 min, 80–95% B; 25–30 min, 95–95% B. Urine analyses were achieved on a TSK-GEL Amide-80 column (150 × 2.0 mm i.d., 5 μm) with a gradient elution program: 0–7 min, 90–90% B; 7–9 min, 90–75% B; 9–11 min, 75–75% B; 11–13 min, 75–50% B; 13–20 min, 50–50% B. Both of the flow rates were set at 0.2 ml/min with the injection volume of 10 μl. The Q-TOF/MS operating parameters were set as follows: fragment voltage, 120 V; nebulizer gas, 35 psig; capillary voltage, 4000 V; drying gas flow rate, 9 L/min; temperature, 325°C; detection range, m/z 50–1,500 in full scan mass spectra. The MS data acquisition was carried out in positive and negative ionization modes.

Validation of System Stability
The repeatability and robustness of the experiment were validated with the pooled quality control sample (QC) (Peron et al., 2020). The QC sample was prepared to mix equal volumes (30 μl) of each test sample, and treated with the same method as the test samples. QC samples were randomly injected throughout the sequence list.

Data Analysis of Metabolomics Strategies
Before multivariate analysis, the data format (.mzdata) files obtained by MassHunter Workstation Software (version B.06.00, Agilent Technologies) were processed by XCMS software performing on the R+ package (R Foundation for Statistical Computing, Vienna, Austria), and the data pretreatment procedures include non-linear retention time alignment, peak discrimination, filtering, alignment, and matching. All detected peaks were tabulated with tR-m/z pairs and outputted for statistical analyses. In order to screen the significant compounds that were responsible for the difference between model and model + EDA, metabolomic strategies were subsequently used to dispose the data. Principal component analysis (PCA), orthogonal partial least square discriminant analysis (OPLS-DA), volcano Plot, and heatmap developed by Metaboanalyst (https://www.metaboanalyst.ca/) were adopted to do the preliminary screening. PCA is a multivariate technique which can select the typical variables from a data table by several linear transformations, and OPLS-DA is a supervised machine learning model. The online database including HMDB (http://www.hmdb.ca/), METLIN (http://metlin.scripps.edu/), and MassBank (http://www.massbank.jp/) was performed to identify the potential metabolites by matching with the message of ion fragments.

Targeted Analysis for Taurine by HPLC-QQQ-MS/MS
Targeted analysis was performed on a triple quadrupole tandem high-performance liquid chromatography-mass spectrometry (HPLC-QQQ-MS/MS) system (Agilent, 6465) with caffeic acid as the internal standard. Chromatographic separation was performed on a TSK-GEL Amide-80 column (150 × 2.0 mm i.d., 5 μm) with a gradient elution program: 0–1 min, 75–75% B;
and multiple comparisons, respectively. Differences were analyzed using two group comparisons (Sham, MCAO/R, and EDA groups, and these groups could be significantly different from each other (Figures 1A–D)).

**Western Blot Analysis**

The RIPA buffer supplemented with protease inhibitor cocktail was adopted for lysing ischemic penumbra of the brain tissues, and obtained samples were used for Western blotting as described previously (Zhai et al., 2017). Protein concentration of tissues was determined by Bicinchoninic Acid (BCA) Protein Assay Kit (Biyuntian Biotech. Co., Ltd., China) after centrifuging (12,000 rpm, 10 min, 4°C). The supernatant was diluted by loading buffer to 1 μg/μl followed by heating at 100°C for 5 min. Equal protein amounts of different groups were electrophoresed on SDS-PAGE gels and transferred to a polyvinylidene fluoride (PVDF) membrane. Then, the obtained PVDF membrane was blocked with 5% BSA solution for 2 h and incubated with specific primary antibodies overnight at 4°C followed by suitable secondary antibodies at room temperature for 2 h. Protein signals were detected with the ECL plus system and imaged by the gel imaging system (BioRad, Hercules, CA, United States). The protein levels were calculated by protein signals to correlative GAPDH or β-actin.

**Immunofluorescence Staining**

After perfusion with PBS and 4% paraformaldehyde, brain tissues were picked up and put into 4% paraformaldehyde. After 24 h, brain tissues were dehydrated with 40% sucrose for 5 days, embedded in OCT, and frozen at ~80°C. Brain tissues were sectioned into slices of 10 μm thickness with a cryotome (Leica, Mannheim, Germany). Brain sections were fixed in 4% paraformaldehyde, permeabilized with 0.3% Triton X-100 in PBS, blocked with 5% bovine serum albumin, and incubated with specific primary antibodies overnight at 4°C. The next day, tissue sections were incubated with appropriate fluorescence-conjugated secondary antibodies at room temperature, and the cell nucleus was stained with DAPI. The immunofluorescence TUNEL assay was performed according to the instructions of the manufacturer. Fluorescent images were observed by confocal laser scanning microscopy (CLSM, LSM700, Zeiss, Germany).

**Statistical Analysis**

Student's t-test and one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test operating on the GraphPad Prism 8.0 (Graph Pad Software, La Jolla, CA, United States) were used for analyzing two group comparisons and multiple comparisons, respectively. Differences were considered significant at p < .05.

## RESULTS

### EDA Effectively Ameliorated Brain Ischemia Reperfusion Injury in Mice

The results of TTC staining demonstrated the marked infarct area of the brain appeared after cerebral I/R and could be reduced by EDA (Figures 1A,B). H&E staining of brain sections showed that cerebral I/R induced cell loss and numerous vacuolated spaces, whereas EDA ameliorated such histopathological damage, as shown in Figure 1C. Additionally, the neurobehavioral deficits could be improved by EDA administration compared with the model group (Figure 1D). The electron microscope was applied for observing the morphology of endothelium, the key elements of the blood–brain barrier. Obviously, the endothelial cells were destroyed after cerebral I/R and improved by EDA (Figure 1E). The morphology of cerebral microvascular endothelial cells in MCAO/R mice changed. Additionally, the cell membrane integrity was also destroyed in MCAO/R mice. These injuries of microvascular endothelial cells could be improved by EDA. Besides, the level of LDH in serum increased in MCAO/R mice and could be significantly inhibited by EDA (Figure 1F). Taken together, EDA effectively alleviated the brain injury and inflammation in MCAO/R mice.

### Multivariate Statistical Analysis of Metabolites in Urine and Serum Samples

Analytical stability was validated by contrasting the difference in retention time of the QC samples. The overlapped total ion chromatograms of QC samples showed that retention time deviation was acceptable (Supplementary Figures 1A–D). Three ions were randomly chosen from QC samples including serum-positive, serum-negative, urine-positive, and urine-negative to evaluate the system reproducibility in the metabolomic raw data acquisition throughout the whole experiment. The relative standard deviations (RSD) of the retention times and corresponding peak areas of the 3 selected ions in the QC samples were 0.59–2.54 and 1.14%–3.78%, as shown in Table 1. The results proved that the repeatability and stability of the HPLC-Q-TOF/MS system were reliable.

PCA was applied to perform unsupervised data analysis on Sham, MCAO/R, and EDA groups, and these groups could be easily distinguished from each other (Figures 2A–D). The phenomenon of the EDA group closing to the sham group compared with the MCAO/R group showed the improvement of EDA on brain injury. To screen the differential compounds that caused the difference between EDA and the model group, OPLS-DA was applied to classify the different samples and select the differential compounds from obtained data. Figures 2E–H suggested that the metabolic profiles in the EDA group were significantly different from those in the MCAO/R group in both urine and serum samples, and the ions of variable importance parameters (VIP > 1) were obtained. S-plot was applied to show those changed ions which significantly contributed to the classification between EDA and MCAO/R group (Figures 2I–L). Depending on VIP > 1 and p-value (p < .05) acquired...
FIGURE 1 | EDA protects against cerebral I/R injury and endothelial injury. Mice were subjected to 1 h of ischemia, followed by 24 h of reperfusion. EDA (3 mg/kg) was administered intraperitoneally after ischemia. (A) Representative TTC-stained brain sections. (B) Quantitative analysis of infarct volume. (C) Stained H&E sections of mice brains. Shrunken cells with pyknotic nuclei are indicated with yellow arrows, while intact cells are indicated with green arrows. (D) Neurological deficit scores in different groups. (E) The structure and morphology of cerebral microvascular endothelial cells in different groups were examined by electron microscopy. Red arrow: brain microvascular endothelial cell membrane. Blue arrow: the degree of edema around brain microvascular endothelial cells. (F) LDH activity. All data are presented as the means ± SEM, n = 6. Scale bar = 50 μm. #p < .05, ##p < .01, ###p < .001, vs. Sham group, *p < .05, **p < .01, ***p < .001, vs. MCAO/R group.

TABLE 1 | Relative standard deviation (RSD%) of retention time and peak area in QC samples.

| Sample | Model | m/z          | Retention time (RSD%) | Peak area (RSD%) |
|--------|-------|--------------|-----------------------|-----------------|
| Serum  | Positive | 203.0541     | 1.34                  | 2.01            |
|        |         | 274.2751     | 0.95                  | 1.93            |
|        |         | 675.6783     | 1.12                  | 3.56            |
|        | Negative | 215.0316     | 1.27                  | 3.78            |
|        |         | 809.2477     | 2.08                  | 2.69            |
|        |         | 279.2312     | 2.54                  | 2.17            |
| Urine  | Positive | 174.1122     | 1.83                  | 2.98            |
|        |         | 114.0654     | 0.81                  | 1.74            |
|        |         | 263.1456     | 1.96                  | 3.14            |
|        |         | 172.9869     | 1.53                  | 1.14            |
|        | Negative | 208.0667     | 0.59                  | 1.22            |
|        |         | 195.0460     | 1.21                  | 1.65            |
through two-tailed Student’s t-test and showed in volcano plot (Figures 3A–D), the variables can be selected for further screening. According to the above screening procedures, the ions were screened and the metabolites were identified, which were considered as potential biomarkers listed in Supplementary Table S1. Comparing EDA and MCAO/R groups, 51 and 56 differential metabolites were identified in serum and urine, respectively. The hierarchical clustering heatmap exhibited the change of metabolites more intuitively (Figures 3E,F). The heatmaps showed that EDA and MCAO/R could be grouped into two parts according to the identified metabolites. The above data exposed that numerous metabolites changed by EDA. Among these metabolites, taurine with 30.795 of fold change showed the greatest change.

Enrichment Analysis of Metabolic Pathway and Regulatory Enzymes Changed by EDA

In order to comprehensively observe the changes in metabolic pathways, Metaboanalyst 4.0 (https://www.metaboanalyst.ca/)
was applied for pathway and biological function enrichment by introducing all significant metabolites of serum and urine. The perturbed pathways including valine, leucine, and isoleucine biosynthesis, and phenylalanine, taurine, and hypotaurine metabolism were screened out (Figures 4A, B). And the correlations between biological functions are also shown in
The results suggested that EDA could improve many pathways under MCAO/R. Moreover, the interaction network of related regulatory enzymes built up with STRING (https://string-db.org/) is exhibited in Supplementary Figure S2A. And the GO enrichment analysis of related regulatory enzymes performed by Metascape (https://www.metascape.org/) showed that cellular amino acid metabolic process, monocarboxylic acid metabolic process, metabolism of lipids, and so on were regulated by EDA (Figure 4D), and the relations of them are exhibited in Supplementary Figure S2B. According to the results described previously, a schematic diagram of the changed metabolic pathways in serum and urine is exhibited in Figure 5.

**Figure 4C**. The results suggested that EDA could improve many pathways under MCAO/R. Moreover, the interaction network of related regulatory enzymes built up with STRING (https://string-db.org/) is exhibited in Supplementary Figure S2A. And the GO enrichment analysis of related regulatory enzymes performed by Metascape (https://www.metascape.org/) showed that cellular amino acid metabolic process, monocarboxylic acid metabolic process, metabolism of lipids, and so on were regulated by EDA (Figure 4D), and the relations of them are exhibited in Supplementary Figure S2B. According to the results described previously, a schematic diagram of the changed metabolic pathways in serum and urine is exhibited in Figure 5.

**Semiquantitative Analysis of Taurine and Validation of CSAD Expression in Pre- and Posttreatment by EDA**

Identification of taurine was characterized by MS profile and confirmed with a standard compound, as shown in Supplementary Figure S3. Analyses of all samples showed that taurine decreased in MCAO/R mice compared with sham groups and could be improved by EDA (Figure 6A). To explore the possible reasons for the change of taurine, the level of CSAD, which is the predominant enzyme that regulates taurine biosynthesis in the brain, was determined. The expression of CSAD in the brain decreased in MCAO/R mice and dramatically increased in mice with the treatment of EDA (Figure 6B). The results of immunofluorescent staining proved the same tendency of CSAD expression in brain ECs (Figures 6C,D). These results demonstrate that the level of taurine was increased by EDA through promoting the expression of CSAD.

**EDA Alleviates MCAO/R Induced Brain EC Apoptosis In Vivo**

As shown in Figures 7A,B, TUNEL assays of brain sections counterstained with CD31 to mark endothelium proved that TUNEL-positive brain ECs increased significantly in the MCAO/R mice, while the number of TUNEL-positive brain ECs was decreased after treatment with EDA. The levels of...
apoptosis proteins were measured with Western blot. The results showed that EDA significantly inhibited the expression of Bax and cleaved caspase-3, and upregulated the expression of Bcl-2 compared with the MCAO/R group (Figures 7C,D). These results suggested that EDA had a protective effect on MCAO/R-induced brain EC apoptosis.

DISCUSSION

In this study, through analysis of high-throughput metabolomics data and multistep validations, we attempted to find the untapped therapeutic targets of EDA, a first-line drug for the clinical treatment of stroke, toward elucidating the therapeutic mechanisms. Initially, we verified that EDA could significantly decrease cerebral infarction, inflammatory infiltration, neurological deficits, endothelium injury, and apoptosis in MCAO/R mice (Figure 1). The above investigations showed that EDA could effectively alleviate the cerebral ischemia-reperfusion injury in MCAO/R mice, thereby providing reliable samples for subsequent metabolomic analysis.

The results of metabolomic analyses presented the metabolic signature of EDA improvement of cerebral I/R injury, offering insights into the therapeutic mechanisms (Figure 5). The metabolites influenced by EDA were mainly lipids, fatty acids in serum, and were mainly amino acids in urine. Notably, oleic acid, linoleic acid, triacylglycerol (TG), palmitic acid, prostaglandin I2, urea, and leucine were reduced by EDA, while sphingosine-1-phosphate, taurine, valine, glutamine, and creatine were improved by EDA, especially taurine (Supplementary Table S1). The increased level of oleic acid leads to mitochondrial-derived reactive oxygen species production, resulting in endothelial dysfunction and blood–brain barrier disruption (Han et al., 2013; Gremmels et al., 2015). Linoleic acid associated with cardiovascular and cerebrovascular diseases significantly activates pro-inflammatory signaling in ECs, such as PI3K/Akt and ERK1/2, thus causing vessel inflammation, endothelial dysfunction, and death (Hennig et al., 2006; Bin et al., 2013; Satoh, 2013; Marchix et al., 2015). Adults with high triacylglycerol have increased risks of incident coronary heart disease and stroke, while lowering triglyceride levels of serum improves endothelial function, leading to a decrease in cardiovascular diseases (Hirano et al., 2008; Kajikawa et al., 2016; Lee et al., 2017). Similarly, the elevated palmitic acid level is related to the development of inflammation and endothelial dysfunction (Yang et al., 2019). Palmitic acid also induces energy metabolism disorders and apoptosis via activation of the apoptotic mitochondrial pathway (Adrian et al., 2017; Wen et al., 2017). Additionally, excess prostaglandin I2, urea, and leucine could similarly result in vascular endothelial injury and even lead to the disruption of barrier (Dorovini-Zis et al., 1987; De Bock et al., 2013; Lau and Vaziri, 2017; d’Apolito et al., 2018; Zhenyukh et al., 2018). Vessel inflammation, endothelial dysfunction, and death were the main factors causing
cardiovascular and cerebrovascular diseases including stroke. Thus, reducing levels of differential metabolites damaging ECs is the potential mechanism of EDA for improving I/R injury. Sphingosine-1-phosphate, a bioactive intermediate of the sphingolipid metabolism, serves important physiological functions, such as proliferation, differentiation, survival, and migration, and is a key regulator of lymphocyte trafficking, endothelial barrier function, and vascular tone (Książek et al., 2015). Taurine, a semi-essential sulfur-containing amino acid, is present in several organs including the brain and has extensive physiological activities such as anti-inflammation and anti-oxidative stress, as well as regulation of energy metabolism, gene expression, osmosis, and quality control of protein. Thus, taurine protects against injuries of ECs and has potential ameliorating effects against cardiovascular diseases and neurological disorder events such as neurodegenerative diseases, stroke, and diabetic neuropathy (Ulrich-Merzenich et al., 2007; Murakami, 2014; Jakaria et al., 2019). Additionally, taurine has been reported to have a protective effect on the brain in stroke by down-regulating PARP and NF-κB, and activating GABAA and glycine receptors, as well as attenuating cell death (Wang GH. et al., 2007; Sun et al., 2012). Valine, one of the eight essential amino acids and sugar-producing amino acids for the human body, could promote the normal growth of the body, regulate protein and energy metabolism, and neurological functions (Shimomura and Kitaura, 2018). Glutamine metabolism is important for ECs in health and disease conditions, especially in cardiovascular diseases. Glutamine not only possesses potent antioxidant and anti-inflammatory effects in the circulation but also drives key processes in vascular cells, including proliferation, migration, apoptosis, senescence, and extracellular matrix deposition by serving as a substrate for the synthesis of DNA, ATP, proteins, and lipids (Rohlenova et al., 2018; Durante, 2019). Creatine exhibits ergogenic effects under a number of conditions including neurodegenerative diseases by maintaining cellular ATP stores. Moreover, creatine could improve ischemic stroke and other cerebrovascular diseases due to antioxidant activity, neurotransmitter-like behavior, and prevention of the opening of the mitochondrial permeability pore (Balestrino et al., 2016). The metabolites described above could replicate some of the previous research findings of the treatment of stroke. In this study, the level of oleic acid and palmitic acid decreased after treating with EDA, which appears to be in line with the treatment of gross saponins of Tribulus.

FIGURE 6 | Effect of EDA on taurine and CSAD in MCAO/R mice. (A) Level of taurine in the different groups. (B) Representative Western blots and quantitative analyses of CSAD expression. (C) Immunofluorescence staining for CSAD (green) and CD31 (red) were performed on frozen brain sections, and the nuclei were counterstained with DAPI (blue) (scale bar = 20 μm). (D) Quantitative analyses of CSAD expression in endothelial cells. All data are presented as the means ± SEM, n = 6. *p < .05, **p < .01, ***p < .001, vs. Sham group, “p < .05, “p < .01, “”p < .001, vs. MCAO/R group.

Ma et al. Metabolomic of Edaravone on Stroke
Similarly, the decrease of phenylalanine was in accordance with the previous report (Fu et al., 2019). Therefore, the possible mechanisms of EDA improvement of stroke were anti-inflammation and anti-oxidative stress, as well as a decrease of endothelial dysfunction and blood–brain barrier disruption by regulating the metabolites described above.

Subsequently, the pathways mediated by EDA were enriched with the differential metabolites. The results highlighted amino acid metabolisms, fatty acid metabolisms, and lipid metabolisms, such as valine, leucine, and isoleucine biosynthesis, biosynthesis of unsaturated fatty acids, sphingolipid metabolism as well as taurine and hypotaurine metabolism pathways (Figures 4A–C).

As described above, valine, leucine, and isoleucine metabolism and most fatty acid metabolisms were directly associated with endothelial dysfunction through increasing reactive oxygen species generation and inflammation, and the change of these pathways, as well as taurine and hypotaurine metabolism, were the important pathological factors in stroke (Hennig et al., 2006; Gremmels et al., 2015; Zhenyukh et al., 2018). Consequently, EDA mainly improves endothelial dysfunction and blood–brain barrier function by interfering with these metabolic pathways, which might be the metabolism mechanism of EDA alleviating cerebral impairment induced by ischemia-reperfusion.

ECs are the key part of the blood–brain barrier which maintains the normal function of the central nervous system and metabolism activity of brain tissue. The death of ECs occurs at the primary stage of stroke which plays a vital role in the early impairment of neurological functions and may interfere with later recovery (Zille et al., 2019). Thus, EC is the potential target mechanism for the treatment of stroke. Interestingly, taurine, one of the mainly increased metabolites by EDA, possesses the effect of endothelium protection. EDA might inhibit the death of ECs by increasing the level of taurine. Hence, taurine was selected for...
the follow-up validation to explore the potential targets of EDA. Our research demonstrated that EDA could effectively elevate the level of taurine. In order to further confirm the mechanism of EDA increase of taurine, the key regulatory enzymes of taurine were verified. CSAD is the key synthetase of taurine and expresses in the brain, while its biofunction in MCAO/R has not been clarified yet (Park et al., 2014). We found that EDA could significantly increase the expression of CSAD, which indicated that EDA might elevate the level of taurine in MCAO/R mice by increasing CSAD. Therefore, CSAD is a potential target of EDA therapy for stroke.

Apoptosis is a common way of cell death, and the apoptosis of ECs is an important pathological process in stroke (Yang et al., 2018). Bax, Bcl-2, and cleaved caspase-3 are the characteristic proteins of apoptosis. We found that EDA could effectively inhibit Bax, Bcl-2, and cleaved caspase-3 by increasing taurine (Figure 7). Thus, EDA inhibited apoptosis of ECs and ameliorated cerebral microvascular endothelial dysfunction, thereby alleviating brain injury induced by I/R. Meanwhile, the EC apoptosis was inhibited along with the expression of CSAD increasing. In summary, taurine and CSAD have a critical role in inhibiting EC apoptosis, which might be an important metabolism mechanism of EDA treatment stroke.

Our current study still has several limitations. EDA treats stroke with many complex mechanisms. Numerous differential metabolites and pathways were found to be associated with therapeutic stroke of EDA. Thus, more differential metabolites need to be further investigated.

CONCLUSION

In the present study, a functional metabolomics strategy was used to characterize metabolite signatures and their underlying mechanisms associated with the therapeutic stroke of EDA. We not only constructed the differential metabolic network map providing clues for investigating mechanisms but also identified the biological function of taurine in the process of EDA improving stroke. It is interesting to note that taurine and its regulatory enzyme CSAD seem to play a key role in inhibiting EC apoptosis induced by I/R. Therefore, this study elucidated that EDA improves stroke via the influence of metabolites and provided a potential therapeutic target for stroke.

REFERENCES

Adrian, L., Lenski, M., Tödter, K., Heeren, J., Böhm, M., and Laufs, U. (2017). AMPK Prevents Palmitic Acid-Induced Apoptosis and Lipid Accumulation in Cardiomyocytes. *Lipids* 52, 737–750. doi:10.1007/s11745-017-4285-7

Amemiya, S., Kamiya, T., Nito, C., Inaba, T., Kato, K., Ueda, M., et al. (2005). Anti-apoptotic and Neuroprotective Effects of Edaravone Following Transient Focal Ischemia in Rats. *Eur. J. Pharmacol.* 516, 125–130. doi:10.1016/j.ejphar.2005.04.036

Alessandro, M., Sarocchi, M., Adriano, E., and Spallarossa, P. (2016). Potential of Creatine or Phosphocreatine Supplementation in Cerebrovascular Disease and in Ischemic Heart Disease. *Amino Acids* 48, 1955–1967. doi:10.1007/s00726-016-2173-8

Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., et al. (2019). Heart Disease and Stroke Statistics-2019 Update: a Report from the American Heart Association. *Circulation* 139, e56–e528. doi:10.1161/CIR.0000000000006559

Bin, Q., Rao, H., Hu, J. N., Liu, R., Fan, Y. W., Li, J., et al. (2013). The Caspase Pathway of Linoleic Acid (9t, 12t-C18:2)-Induced Apoptosis in Human Umbilical Vein Endothelial Cells. *Lipids* 48, 115–126. doi:10.1007/s11745-012-3728-4

Cao, G., Jiang, N., Hu, Y., Zhang, Y., Wang, G., Yin, M., et al. (2016). Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of the Animal Ethics Committee of the School of Chinese Materia Medica, China Pharmaceutical University.

AUTHOR CONTRIBUTIONS

H-fM, S-sG and J-pK conceived this project and designed the experiments. H-fM, FZ and L-jS performed most experiments and interpreted the data. D-wZ and Y-nL collected samples. FZ and Y-yZ aided in the data analysis. H-fM wrote the manuscript. J-pK, S-sG and FL revised the manuscript. All authors read and approved the final article.

FUNDING

This research was supported by the National Natural Science Foundation of China (Nos. 82074058, 82104438, and 82104437). Project funded by the China Postdoctoral Science Foundation (Nos. 2021M693518 and 2021M693519), the Natural Science Foundation of Jiangsu Province (Nos. SBK20210432 and SBK20210431), and the National Science Foundation for the third batch of special funding for postdoctoral fellows (No. 2021TQ0367), and supported by “Double First-Class” University project (CPU2018GF07). This research project was supported by the grant from China Pharmaceutical University.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.814942/full#supplementary-material
and the MAPK Pathway. *Int. J. Mol. Sci.* 17, 1418. doi:10.3390/ijms17091418

d’Apolito, M., Colla, A. L., Manca, E., Petroillo-Mantovani, M., Sacco, M., Maffione, A. B., et al. (2018). Urea Memory: Transient Cell Exposure to Urea Causes Persistent Mitochondrial ROS Production and Endothelial Dysfunction. *Toxins (Basel)* 10, 410. doi:10.3390/toxins10110410

De Bock, M., Wang, N., Decrock, E., Bol, M., Gadicherla, A. K., Culot, M., et al. (2013). Endothelial Calcium Dynamics, Connexin Channels and Blood-Brain Barrier Function. *Prog. Neurobiol.* 108, 1–20. doi:10.1016/j.pneurobio.2013.06.001

Dorovini-Zis, K., Bowman, P. D., Betz, A. L., and Goldstein, G. W. (1987).

Kikuchi, K., Tancharoen, S., Takeshige, N., Yoshitomi, M., Morioka, M., Murai, Y., Kajikawa, M., Maruhashi, T., Matsumoto, T., Iwamoto, Y., Iwamoto, A., Oda, N., Jakaria, M., Azam, S., Haque, M. E., Jo, S. H., Uddin, M. S., Kim, I. S., et al. (2019). Metabolomic of Edaravone on Stroke. *Frontiers in Pharmacology* | www.frontiersin.org February 2022 | Volume 13 | Article 814942

Hirano, K., Ikeda, Y., Zaima, N., Sakata, Y., and Matsumiya, G. (2008). Triglyceride Gremmels, H., Bevers, L. M., Fledderus, J. O., Braam, B., van Zonneveld, A. J., Frontiers in Pharmacology | www.frontiersin.org February 2022 | Volume 13 | Article 814942

Hennig, B., Lei, W., Arzuaga, X., Ghosh, D. D., Saraswathi, V., and Toborek, M. et al. (2013). The Effect of Taurine against Ischemic Stroke Is Related to Down-Regulation of PARP and NK-β. *Amino acids* 42, 1735–1747. doi:10.1007/s00726-011-0885-3

Ulrich-Merzenich, G., Zeiter, H., Vetter, H., and Bhonde, R. R. (2007). Protective Effect of Taurine on Endothelial Cells Impaired by High Glucose and Oxidized Low Density Lipoproteins. *Eur. J. Nutr.* 46, 431–438. doi:10.1007/s00394-007-0682-7

Wang, G. H., Jiang, Z. L., Fan, X. J., Zhang, L., Li, X., and Ke, K. F. (2007a). Neuroprotective Effect of Taurine against Focal Cerebral Ischemia in Rats Possibly Mediated by Activation of Both GABAA and glycine Receptors. *Neuropharmacology* 52, 1199–1209. doi:10.1016/j.neuropharm.2006.10.022

Wang, Q., Luo, W., Zheng, W., Liu, X., Xu, H., Zheng, G., et al. (2007b). Iron Supplement Prevents lead-induced Disruption of the Blood-Brain Barrier during Rat Development. *Toxicol. Appl. Pharmacol.* 219, 33–41. doi:10.1016/j.taap.2006.11.035

Wang, Y., Zhao, H., Liu, Y., Guo, W., Bao, Y., Zhang, M., et al. (2019). GC-MS-based Metabolomics to Reveal the Protective Effect of Gross Saponins of Tribulus Terrestris Fruit against Ischemic Stroke. *Food Res. Int.* 128, 109682. doi:10.1016/j.foodres.2019.108730

Wen, S. Y., Velmurugan, B. K., Day, C. H., Shen, C. Y., Chuin, L. C., Tsai, Y. C., et al. (2017). High Density Lipoprotein (HDL) Reverses Palmitic Acid Induced Energy Metabolism Imbalance by Switching CD36 and GLUT4 Signaling Pathways in Cardiomyocyte. *J. Cel Physiol.* 232, 3020–3029. doi:10.1002/jcp.26007

Yung, H. X., Xiao, X., Zhao, B., Su, Z., and Wang, Z. (2018). KLF4 Protects Brain Microvascular Endothelial Cells from Ischemic Stroke Induced Apoptosis by Transcriptionally Activating MALAT1. *Biochem. Biophys. Res. Commun.* 495, 2376–2382. doi:10.1016/j.bbrc.2017.11.025

Yung, Q., Han, L., Li, J., Xu, H., Liu, X., Wang, X., et al. (2019). Activation of Nrf2 by Phloretin Attenuates Palmitic Acid-Induced Endothelial Cell Oxidative Stress via AMPK-dependent Signaling. *J. Agric. Food Chem.* 67, 120–131. doi:10.1021/acs.jafc.8b05025

Yung, H. W., Korolchuk, S., Tolkovsky, A. M., Charnock-Jones, D. S., and Burton, G. J. (2007). Endoplasmic Reticulum Stress Exacerbates Ischemia-Reperfusion-Induced Apoptosis through Attenuation of Akt Protein Synthesis in Human Choriocarcinoma Cells. *Faseb. J.* 21, 872–884. doi:10.1096/fj.06-0504cm

Zhai, K. F., Zheng, J. R., Tang, Y. M., Li, F., Lv, Y. N., Zhang, Y. Y., et al. (2017). The Saponin D39 Blocks Dissociation of Non-muscular Myosin Heavy Chain IIA from TNF Receptor 2, Suppressing Tissue Factor Expression and Venous Thrombosis. *Br. J. Pharmacol.* 174, 2818–2831. doi:10.1111/bph.13885

Zhang, N., Komine-Kobayashi, M., Tanaka, R., Liu, M., Mizuno, Y., and UraBE, T. (2005). Edaravone Reduces Early Accumulation of Oxidative Products and Sequential Inflammatory Responses after Transient Focal

Ma et al. Metabolomic of Edaravone on Stroke
Ischemia in Mice Brain. Stroke 36, 2220–2225. doi:10.1161/01.STR.0000182241.07096.06
Zhenyukh, O., González-Amor, M., Rodríguez-Diez, R. R., Esteban, V., Ruiz-Ortega, M., Salaices, M., et al. (2018). Branched-chain Amino Acids Promote Endothelial Dysfunction through Increased Reactive Oxygen Species Generation and Inflammation. J. Cel Mol. Med. 22, 4948–4962. doi:10.1111/jcmm.13759
Zille, M., Ikhsan, M., Jiang, Y., Lampe, J., Wenzel, J., and Schwaninger, M. (2019). The Impact of Endothelial Cell Death in the Brain and its Role after Stroke: A Systematic Review. Cell Stress 3, 330–347. doi:10.15698/cst2019.11.203

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ma, Zheng, Su, Zhang, Liu, Li, Zhang, Gong and Kou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.